3,5-dihydro-imidazo[4,5-d]pyridazin-4-ones:: A class of potent DPP-4 inhibitors

被引：33

作者：

Eckhardt, Matthias ^{[1
]}

Hauel, Norbert ^{[1
]}

Himmelsbach, Frank ^{[1
]}

Langkopf, Elke ^{[1
]}

Nar, Herbert ^{[2
]}

Mark, Michael ^{[3
]}

Tadayyon, Moh ^{[3
]}

Thomas, Leo ^{[3
]}

Guth, Brian ^{[4
]}

Lotz, Ralf ^{[4
]}

机构：

[1] Boehringer Ingelheim Pharma GmbH & Co KG, Dept Chem Res, D-88400 Biberach, Germany

[2] Boehringer Ingelheim Pharma GmbH & Co KG, Dept Lead Discovery, D-88400 Biberach, Germany

[3] Boehringer Ingelheim Pharma GmbH & Co KG, Dept Metabol Dis Res, D-88400 Biberach, Germany

[4] Boehringer Ingelheim Pharma GmbH & Co KG, Dept Drug Discovery Support, D-88400 Biberach, Germany

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2008年 / 18卷 / 11期

关键词：

dipeptidyl peptidase 4; DPP-4; imidazopyridazinones;

D O I：

10.1016/j.bmcl.2008.04.075

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Systematic variations of the xanthine scaffold in close analogs of development compound BI 1356 led to the class of 3,5-dihydro-imidazo[4,5-d]pyridazin-4-ones which provided, after substituent screening, a series of highly potent DPP-4 inhibitors. (C) 2008 Elsevier Ltd. All rights reserved.

引用

页码：3158 / 3162

页数：5

共 13 条

[1] Inhibitors of proline-specific a dipeptidyl peptidases: DPP IV inhibitors as a novel approach for the treatment of Type 2 diabetes [J].

Augustyns, K ;

Van der Veken, P ;

Haemers, A .

EXPERT OPINION ON THERAPEUTIC PATENTS, 2005, 15 (10) :1387-1407

[2]

ECKHARDT M, 2006, Patent No. 2006000354

[3] Synthesis of 2-bromo-7-methyl-3,5-dihydro-imidazo[4,5-d]pyridazin-4-one and 3-alkyl-2-bromo-3,5-dihydro-imidazo[4,5-d]pyridazin-4-one and their selective elaboration [J].

Eckhardt, Matthias ;

Hauel, Norbert ;

Langkopf, Elke ;

Himmelsbach, Frank .

TETRAHEDRON LETTERS, 2008, 49 (12) :1931-1934

[4] 8-(3-(R)-aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydropurine-2,6-dione (BI 1356), a highly potent, selective, long-acting, and orally bioavailable DPP-4 inhibitor for the treatment of type 2 diabetes [J].

Eckhardt, Matthias ;

Langkop, Elke ;

Mark, Michael ;

Tadayyon, Mob ;

Thomas, Leo ;

Nar, Herbert ;

Pfrengle, Waldemar ;

Guth, Brian ;

Lotz, Ralf ;

Sieger, Peter ;

Fuchs, Holger ;

Himmelsbach, Frank .

JOURNAL OF MEDICINAL CHEMISTRY, 2007, 50 (26) :6450-6453

[5] GLP-1 receptor agonists are growth and differentiation factors for pancreatic istet beta cells [J].

Egan, JM ;

Bulotta, A ;

Hui, HX ;

Perfetti, R .

DIABETES-METABOLISM RESEARCH AND REVIEWS, 2003, 19 (02) :115-123

[6]

Kauffmann-Hefner I., 2004, PCT Int. Appl, Patent No. [2004050658, WO 2004050658]

[7] DEGRADATION OF GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE AND TRUNCATED GLUCAGON-LIKE PEPTIDE-1 IN-VITRO AND IN-VIVO BY DIPEPTIDYL PEPTIDASE-IV [J].

KIEFFER, TJ ;

MCINTOSH, CHS ;

PEDERSON, RA .

ENDOCRINOLOGY, 1995, 136 (08) :3585-3596

[8] Xanthine mimetics as potent dipeptidyl peptidase IV inhibitors [J].

Kurukulasuriya, Ravi ;

Rohde, Jeffrey J. ;

Szczepankiewicz, Bruce G. ;

Basha, Fatima ;

Lai, Chunqui ;

Jae, Hwan-Soo ;

Winn, Martin ;

Stewart, Kent D. ;

Longenecker, Kenton L. ;

Lubben, Thomas W. ;

Ballaron, Stephen J. ;

Sham, Hing L. ;

von Geldern, Thomas W. .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2006, 16 (24) :6226-6230

[9] Dipeptidyl peptidase iv inhibitors and diabetes therapy [J].

McIntosh, Christopher H. S. .

FRONTIERS IN BIOSCIENCE-LANDMARK, 2008, 13 :1753-1773

[10] Gut peptides in the regulation of food intake and energy homeostasis [J].

Murphy, Kevin G. ;

Dhillo, Waljit S. ;

Bloom, Stephen R. .

ENDOCRINE REVIEWS, 2006, 27 (07) :719-727

← 1 2 →